901494
N-Methylated pomalidomide
≥98%
别名:
4-Amino-2-(1-methyl-2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione, E3 Ligase ligand methylated negative control, Ligand for PROTAC® research
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C14H13N3O4
化学文摘社编号:
分子量:
287.27
MDL number:
UNSPSC Code:
12352101
NACRES:
NA.22
Assay:
≥98%
Form:
powder or crystals
ligand
N-Methylated Pomalidomide
Quality Level
assay
≥98%
form
powder or crystals
reaction suitability
reagent type: ligand
shipped in
wet ice
storage temp.
2-8°C
SMILES string
O=C(C(CC1)N(C2=O)C(C3=C2C=CC=C3N)=O)N(C)C1=O
InChI
1S/C14H13N3O4/c1-16-10(18)6-5-9(13(16)20)17-12(19)7-3-2-4-8(15)11(7)14(17)21/h2-4,9H,5-6,15H2,1H3
InChI key
YSWQOCGODHPKED-UHFFFAOYSA-N
Application
N-Methylated pomalidomide is a ligand used as a negative control for pomalidomide (P0018) in the recruitment of the Cereblon (CRBN) protein for targeted protein degradation and PROTAC (proteolysis-targeting chimeras) technology.
Other Notes
Technology Spotlight: Degrader Building Blocks for Targeted Protein Degradation
Portal: Building PROTAC® Degraders for Targeted Protein Degradation
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Targeted Protein Degradation by Small Molecules
Small-Molecule PROTACS: New Approaches to Protein Degradation
Portal: Building PROTAC® Degraders for Targeted Protein Degradation
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Targeted Protein Degradation by Small Molecules
Small-Molecule PROTACS: New Approaches to Protein Degradation
Legal Information
PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
商品
Protein Degrader Building Blocks are a collection of crosslinker-E3 ligand conjugates with a pendant functional group for covalent linkage to a target ligand.
Jing Lu et al.
Chemistry & biology, 22(6), 755-763 (2015-06-09)
BRD4, a bromodomain and extraterminal domain (BET) family member, is an attractive target in multiple pathological settings, particularly cancer. While BRD4 inhibitors have shown some promise in MYC-driven malignancies such as Burkitt's lymphoma (BL), we show that BRD4 inhibitors lead to
Momar Toure et al.
Angewandte Chemie (International ed. in English), 55(6), 1966-1973 (2016-01-13)
The current inhibitor-based approach to therapeutics has inherent limitations owing to its occupancy-based model: 1) there is a need to maintain high systemic exposure to ensure sufficient in vivo inhibition, 2) high in vivo concentrations bring potential for off-target side effects, and 3) there is
Momar Toure et al.
Angewandte Chemie (International ed. in English), 55(6), 1966-1973 (2016-01-13)
The current inhibitor-based approach to therapeutics has inherent limitations owing to its occupancy-based model: 1) there is a need to maintain high systemic exposure to ensure sufficient in vivo inhibition, 2) high in vivo concentrations bring potential for off-target side effects, and 3) there is
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 901494-25MG | 04061834671558 |
| 901494-10MG-KC | 04065272218047 |